{
  "symbol": "DYAI",
  "company_name": "Dyadic International",
  "ir_website": "https://www.dyadic.com/investors",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Q3-2024 Conference Call 11/12/2024 5:00 pm ET.",
          "url": "https://viavid.webcasts.com/starthere.jsp?ei=1650834&tp_key=6f648c5876",
          "content": "![](https://cache.webcasts.com/content/viav001/1650834/content/6f648c5876cd516b40ad58e90e7bf0549372f457/banner/Dyadic.png)\n\n[![](/viewer/images/help.png) FAQs and System Test](#)\n\n# Dyadic International, Inc Third Quarter 2024 Financial Results Conference Call\n\n### Tue, Nov 12, 2024 5:00 PM EST\n\nAlready Registered? Log In Now  \n---  \nEmail:  \n  \nComplete this form to enter the webcast. (* indicates required field)\n\nEmail*:  \n---  \nFirst Name*:  \nLast Name*:  \nCompany*:  \nPhone Number*:  \n  \n[![Webcast by GlobalMeet](/viewer/images/webcastbygm.png)](https://www.globalmeet.com)\n\n  * [Outlook ❯](#)\n  * [Google ❯](#)\n\n\n"
        },
        {
          "title": "Investor Fact Sheet",
          "url": "https://dyadic.com/investors/overview/#factsheet",
          "content": "[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n#### INVESTORS\n\n# Overview\n\n## Dyadic International, Inc. (NASDAQ: DYAI)\n\nDyadic International, Inc. (NASDAQ: DYAI) –. We are a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health.\n\nWith a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based microbial platform technologies, including C1 and Dapibus™.\n\n  * [Overview](https://dyadic.com/investors/overview/)\n  * [Corporate Profile](https://dyadic.com/investors/corporate-profile/)\n  * [Press Releases](https://dyadic.com/investors/press-releases/)\n  * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n  * [Financials](https://dyadic.com/investors/financials/)\n  * [Investor Fact Sheet](/investors/overview/#factsheet)\n  * [Presentations](https://dyadic.com/investors/presentations/)\n  * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n  * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n  * [Stock Info / Analyst Coverage](https://dyadic.com/investors/stock-information/)\n  * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n\n\n\n## Company Contact\n\n**PING W. RAWSON** Email: ir@dyadic.com Phone: 561-743-8333\n\n## Transfer Agent\n\n**Continental Stock Transfer & Trust **1 State St., 30th Floor New York, NY 10004-1561 212-509-4000 or 800-509-5586\n\n## Company Events\n\n## Investor Fact Sheet\n\n## Press Releases\n\n[All Press Releases](https://dyadic.com/investors/press-releases/)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://dyadic.com/investors/sec-filings/",
          "content": "[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n#### INVESTORS\n\n# SEC Filings\n\n## Dyadic International, Inc. (NASDAQ: DYAI)\n\nWe are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.\n\nWith a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based\n\n  * [Overview](https://dyadic.com/investors/overview/)\n  * [Corporate Profile](https://dyadic.com/investors/corporate-profile/)\n  * [Press Releases](https://dyadic.com/investors/press-releases/)\n  * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n  * [Financials](https://dyadic.com/investors/financials/)\n  * [Investor Fact Sheet](/investors/overview/#factsheet)\n  * [Presentations](https://dyadic.com/investors/presentations/)\n  * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n  * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n  * [Stock Info / Analyst Coverage](https://dyadic.com/investors/stock-information/)\n  * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n\n\n\n## Company Contact\n\n**PING W. RAWSON** Email: ir@dyadic.com Phone: 561-743-8333\n\n## Transfer Agent\n\n**Continental Stock Transfer & Trust **1 State St., 30th Floor New York, NY 10004-1561 212-509-4000 or 800-509-5586\n\n## Latest Quarterly\n\n## All SEC Filings\n"
        },
        {
          "title": "Financials",
          "url": "https://dyadic.com/investors/financials/",
          "content": "[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n#### INVESTORS\n\n# Financials\n\n## Dyadic International, Inc. (NASDAQ: DYAI)\n\nWe are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.\n\nWith a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based\n\n  * [Overview](https://dyadic.com/investors/overview/)\n  * [Corporate Profile](https://dyadic.com/investors/corporate-profile/)\n  * [Press Releases](https://dyadic.com/investors/press-releases/)\n  * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n  * [Financials](https://dyadic.com/investors/financials/)\n  * [Investor Fact Sheet](/investors/overview/#factsheet)\n  * [Presentations](https://dyadic.com/investors/presentations/)\n  * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n  * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n  * [Stock Info / Analyst Coverage](https://dyadic.com/investors/stock-information/)\n  * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n\n\n\n## Company Contact\n\n**PING W. RAWSON** Email: ir@dyadic.com Phone: 561-743-8333\n\n## Transfer Agent\n\n**Continental Stock Transfer & Trust **1 State St., 30th Floor New York, NY 10004-1561 212-509-4000 or 800-509-5586\n"
        }
      ]
    },
    {
      "section_name": "Analyst Coverage",
      "links": [
        {
          "title": "Analyst Coverage",
          "url": "https://dyadic.com/investors/analyst-coverage/",
          "content": "[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n#### INVESTORS\n\n# Analyst Coverage\n\n## Dyadic International, Inc. (NASDAQ: DYAI)\n\nWe are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.\n\nWith a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based\n\n  * [Overview](https://dyadic.com/investors/overview/)\n  * [Corporate Profile](https://dyadic.com/investors/corporate-profile/)\n  * [Press Releases](https://dyadic.com/investors/press-releases/)\n  * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n  * [Financials](https://dyadic.com/investors/financials/)\n  * [Investor Fact Sheet](/investors/overview/#factsheet)\n  * [Presentations](https://dyadic.com/investors/presentations/)\n  * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n  * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n  * [Stock Info / Analyst Coverage](https://dyadic.com/investors/stock-information/)\n  * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n\n\n\n## Company Contact\n\n**PING W. RAWSON** Email: ir@dyadic.com Phone: 561-743-8333\n\n## Transfer Agent\n\n**Continental Stock Transfer & Trust **1 State St., 30th Floor New York, NY 10004-1561 212-509-4000 or 800-509-5586\n\n## Analyst Coverage\n"
        }
      ]
    },
    {
      "section_name": "Annual Meeting and Proxy",
      "links": [
        {
          "title": "Annual Meeting and Proxy",
          "url": "https://dyadic.com/investors/annual-meeting-and-proxy/",
          "content": "[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n#### INVESTORS\n\n# Annual Meeting and Proxy\n\n## Dyadic International, Inc. (NASDAQ: DYAI)\n\nWe are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.\n\nWith a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based\n\n  * [Overview](https://dyadic.com/investors/overview/)\n  * [Corporate Profile](https://dyadic.com/investors/corporate-profile/)\n  * [Press Releases](https://dyadic.com/investors/press-releases/)\n  * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n  * [Financials](https://dyadic.com/investors/financials/)\n  * [Investor Fact Sheet](/investors/overview/#factsheet)\n  * [Presentations](https://dyadic.com/investors/presentations/)\n  * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n  * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n  * [Stock Info / Analyst Coverage](https://dyadic.com/investors/stock-information/)\n  * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n\n\n\n## Company Contact\n\n**PING W. RAWSON** Email: ir@dyadic.com Phone: 561-743-8333\n\n## Transfer Agent\n\n**Continental Stock Transfer & Trust **1 State St., 30th Floor New York, NY 10004-1561 212-509-4000 or 800-509-5586\n"
        }
      ]
    },
    {
      "section_name": "Earnings Calls",
      "links": [
        {
          "title": "Earnings Calls",
          "url": "https://dyadic.com/investors/earnings-calls/",
          "content": "[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n[![](https://dyadic.com/wp-content/uploads/2024/02/Dyadic-International-Logo-3x3-1-150x150.png)](/)\n\n  * [About Us](/company-history/)\n    * [Company History](https://dyadic.com/company-history/)\n    * [Our Mission](https://dyadic.com/our-mission/)\n    * [Management Team](https://dyadic.com/about-us/management/)\n    * [Board of Directors](https://dyadic.com/about-us/directors/)\n[](#)\n  * [Technology](/science/the-problem/)\n    * [The Problem](https://dyadic.com/science/the-problem/)\n    * [The Solution: Our Microbial Platforms](https://dyadic.com/science/the-solution-our-platform/)\n      * [C1](https://dyadic.com/science/the-solution-our-platform/c1/)\n      * [Dapibus™](https://dyadic.com/science/the-solution-our-platform/dapibus/)\n[](#)\n    * [Advantages and Opportunities](https://dyadic.com/science/advantages-and-opportunities/)\n[](#)\n  * [Pipeline](https://dyadic.com/pipelines/)\n    * [Human Health](https://dyadic.com/pipelines/human-health/)\n    * [Animal Health](https://dyadic.com/pipelines/animal-health/)\n    * [Alternative Proteins](https://dyadic.com/pipelines/alternative-proteins/)\n[](#)\n  * [Partners](https://dyadic.com/partners/)\n  * [Investors](https://dyadic.com/investors/overview/)\n    * [Overview](https://dyadic.com/investors/overview/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n    * [Financials](https://dyadic.com/investors/financials/)\n    * [Investor Fact Sheet](/investors/overview/#factsheet)\n    * [Analyst Coverage](https://dyadic.com/investors/analyst-coverage/)\n    * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n    * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n    * [Stock Information](https://dyadic.com/investors/stock-information/)\n    * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n    * [Email Alert Opt-in](https://dyadic.com/investors/email-alert-opt-in/)\n[](#)\n  * [Media](/articles/)\n    * [Articles](https://dyadic.com/articles/)\n    * [Events](https://dyadic.com/media-events/)\n    * [Presentations](https://dyadic.com/investors/presentations/)\n    * [Press Releases](https://dyadic.com/investors/press-releases/)\n    * [Scientific Publications](https://dyadic.com/scientific-publications/)\n    * [Video Gallery](https://dyadic.com/video-gallery/)\n[](#)\n  * [Contact Us](https://dyadic.com/contact-us/)\n\n\n\n#### INVESTORS\n\n# Earnings Calls\n\n## Dyadic International, Inc. (NASDAQ: DYAI)\n\nWe are a global biotechnology company committed to building disruptive microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.\n\nWith a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary filamentous fungal based\n\n  * [Overview](https://dyadic.com/investors/overview/)\n  * [Corporate Profile](https://dyadic.com/investors/corporate-profile/)\n  * [Press Releases](https://dyadic.com/investors/press-releases/)\n  * [SEC Filings](https://dyadic.com/investors/sec-filings/)\n  * [Financials](https://dyadic.com/investors/financials/)\n  * [Investor Fact Sheet](/investors/overview/#factsheet)\n  * [Presentations](https://dyadic.com/investors/presentations/)\n  * [Corporate Governance](https://dyadic.com/investors/corporate-governance/)\n  * [Annual Meeting and Proxy](https://dyadic.com/investors/annual-meeting-and-proxy/)\n  * [Stock Info / Analyst Coverage](https://dyadic.com/investors/stock-information/)\n  * [Earnings Calls](https://dyadic.com/investors/earnings-calls/)\n\n\n\n## Company Contact\n\n**PING W. RAWSON** Email: ir@dyadic.com Phone: 561-743-8333\n\n## Transfer Agent\n\n**Continental Stock Transfer & Trust **1 State St., 30th Floor New York, NY 10004-1561 212-509-4000 or 800-509-5586\n\n## Upcoming Events\n\n## Past Events\n"
        }
      ]
    }
  ]
}